- Ampio Pharmaceuticals (AMPE) is out with more data from SPRING (see initial read-out from August) which shows Ampion achieved "significant results [on] secondary end points."
- Reduction in pain versus saline was significant across the entire 12-week period.
- A single injection produced "a clinically and statistically significant reduction in pain, with an estimated difference from control at the study endpoint of -0.25 on the WOMAC A scale." (PR)
Ampio Pharmaceuticals reports additional Ampion data
Sep 30 2013, 08:32 ET